Positive preliminary results have been reported from two pilot clinical trials evaluating the efficacy and safety of the investigational chimeric antigen receptor therapy CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia . The studies, conducted at the University of Pennsylvania's Perelman School of Medicine, demonstrated that 27 of 30 pediatric and adult patients experienced complete remissions after treatment with CTL019.
http://ift.tt/1vBugD6
http://ift.tt/1vBugD6
No comments:
Post a Comment